{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:37:50Z","timestamp":1793065070708,"version":"4.5.0"},"reference-count":44,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.2967\/jnumed.124.268903","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T16:10:15Z","timestamp":1739463015000},"page":"449-456","source":"Crossref","is-referenced-by-count":36,"title":["Dosimetry of [\n                    <sup>177<\/sup>\n                    Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial"],"prefix":"10.2967","volume":"66","author":[{"given":"Lisa","family":"Bodei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cremonesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahila","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Mittra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaventhan","family":"Srirajaskanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Grana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Miederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Chicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio F.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Demange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack L.","family":"Erion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germo","family":"Gericke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2025030410451222000_66.3.449.1","unstructured":"Lutathera summary of product characteristics. European Medicines Agency website. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lutathera-epar-product-information_en.pdf. Updated 2017. Accessed June 20, 2024."},{"key":"2025030410451222000_66.3.449.2","unstructured":"Pharmaceutical Safety and Environmental Health Bureau audit report: Lutetium oxodotreotide (177Lu) [in Japanese]. Pharmaceutical and Medical Devices Agency (Japan) website. https:\/\/www.pmda.go.jp\/drugs\/2021\/P20210701003\/400022000_30300AMX00289_A100_1.pdf. Updated 2021. Accessed June 20, 2024."},{"key":"2025030410451222000_66.3.449.3","unstructured":"Lutathera highlights of prescribing information. U.S. Food and Drug Administration website. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/lutathera.pdf. Updated March 2023. Accessed June 20, 2024."},{"key":"2025030410451222000_66.3.449.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2025030410451222000_66.3.449.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025030410451222000_66.3.449.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2025030410451222000_66.3.449.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"2025030410451222000_66.3.449.8","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.449.9","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050462"},{"key":"2025030410451222000_66.3.449.10","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100574"},{"key":"2025030410451222000_66.3.449.11","first-page":"37S","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med."},{"key":"2025030410451222000_66.3.449.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90064-6"},{"key":"2025030410451222000_66.3.449.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2025030410451222000_66.3.449.14","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"key":"2025030410451222000_66.3.449.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1072-6"},{"key":"2025030410451222000_66.3.449.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2025030410451222000_66.3.449.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262749"},{"key":"2025030410451222000_66.3.449.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2025030410451222000_66.3.449.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107524"},{"key":"2025030410451222000_66.3.449.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3193-4"},{"key":"2025030410451222000_66.3.449.21","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.449.22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.449.23","first-page":"37","article-title":"Dosimetry for treatment with radiolabelled somatostatin analogues: a review","volume":"54","author":"Cremonesi","year":"2010","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.449.24","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0641"},{"key":"2025030410451222000_66.3.449.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.249136"},{"key":"2025030410451222000_66.3.449.26","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.449.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3945-z"},{"key":"2025030410451222000_66.3.449.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.225235"},{"key":"2025030410451222000_66.3.449.29","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1200\/JCO.2021.39.15_suppl.4112","article-title":"Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors","volume":"39","author":"Strosberg","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025030410451222000_66.3.449.30","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers13050962","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms","volume":"13","author":"Jahn","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2025030410451222000_66.3.449.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262069"},{"key":"2025030410451222000_66.3.449.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.148437"},{"key":"2025030410451222000_66.3.449.33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/biomedicines4040025","article-title":"Personalized dosimetry for radionuclide therapy using molecular imaging tools","volume":"4","author":"Ljungberg","year":"2016","journal-title":"Biomedicines."},{"key":"2025030410451222000_66.3.449.34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","article-title":"Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Rosar","year":"2021","journal-title":"EJNMMI Phys."},{"key":"2025030410451222000_66.3.449.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266063"},{"key":"2025030410451222000_66.3.449.36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","article-title":"Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT)","volume":"31","author":"Schiavo Lena","year":"2020","journal-title":"Endocr Pathol."},{"key":"2025030410451222000_66.3.449.37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13244-021-01017-2","article-title":"Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe","volume":"12","author":"Albano","year":"2021","journal-title":"Insights Imaging."},{"key":"2025030410451222000_66.3.449.38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2020.00193","article-title":"Tumor contrast-enhancement for monitoring of PRRT 177Lu-DOTATATE in pancreatic neuroendocrine tumor patients","volume":"10","author":"Pettersson","year":"2020","journal-title":"Front Oncol."},{"key":"2025030410451222000_66.3.449.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.12.003"},{"key":"2025030410451222000_66.3.449.40","doi-asserted-by":"crossref","first-page":"v564","DOI":"10.1093\/annonc\/mdz256.002","article-title":"Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population","volume":"30","author":"Pavel","year":"2019","journal-title":"Ann Oncol."},{"key":"2025030410451222000_66.3.449.41","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1159\/000504001","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy: dose response in small intestinal neuroendocrine tumors","volume":"110","author":"Jahn","year":"2020","journal-title":"Neuroendocrinology."},{"key":"2025030410451222000_66.3.449.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265987"},{"key":"2025030410451222000_66.3.449.43","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.23.01241","article-title":"How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and phase I clinical trial design","volume":"42","author":"Kiess","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025030410451222000_66.3.449.44","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262305"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:45:51Z","timestamp":1741095951000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.2967\/jnumed.124.268903"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268903","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}